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Abstract
Epidemiologic studies have observed association between short sleep duration and both cardiovascular disease
(CVD) and type 2 diabetes, although these results may reflect confounding by pre-existing illness. This study aimed
to determine whether short sleep duration predicts future CVD or type 2 diabetes after accounting for baseline health.
Baseline data for 241,949 adults were collected through the 45 and Up Study, an Australian prospective cohort study,
with health outcomes identified via electronic database linkage. Cox proportional hazards models were used to
estimate hazard ratios (HR) and 95% confidence intervals. Compared to 7h sleep, <6h sleep was associated with
incident CVD in participants reporting ill-health at baseline (HR=1·38 [95% CI: 1·12-1·70]), but not after excluding
those with baseline illness and adjusting for baseline health status (1·03 [0·88-1·21]). In contrast, the risk of incident
type 2 diabetes was significantly increased in those with <6h versus 7h sleep, even after excluding those with
baseline illness and adjusting for baseline health (HR=1·29 [1·08-1·53], P=0.004). This suggests the association is
valid and does not simply reflect confounding or reverse causation. Meta-analysis of ten prospective studies including
447,124 participants also confirmed an association between short sleep and incident diabetes (1·33 [1·20-1·48]).
Obtaining less than 6 hours of sleep each night (compared to 7 hours) may increase type 2 diabetes risk by
approximately 30%.
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Introduction
The World Health Organization (WHO) recently published a
global strategy to “prevent and control” major
noncommunicable diseases such as CVD and type 2 diabetes,
with a key emphasis upon reducing exposure to established
risk factors [1]. A potential risk factor for cardiometabolic
disease is sleep duration. Various epidemiologic studies have
observed associations of either deficient or excessive sleep
duration with cardiometabolic disease, albeit with uncertain
causality. Given the burgeoning global prevalence of
cardiovascular disease and type 2 diabetes, and high levels of
voluntary and involuntary sleep curtailment, a causal effect of
sleep duration upon cardiometabolic disease risk has
considerable implications for public health.
In relation to whether sleep duration predicts future, incident
CVD, prospective studies have produced conflicting results.
Different studies have alternatively reported prediction of future
CVD by long sleep duration alone [2,3], short sleep duration
alone [4–6], both short and long sleep duration (U-shaped
relationship) [7–10] and neither short nor long sleep duration
[11,12]. Several individual studies have reported substantial
attenuation or abolition of apparent associations after statistical
adjustment for covariates [5,11,13], suggesting that apparent
associations may reflect residual confounding. In contrast,
prospective studies [14–19] and a meta-analysis [20] have
provided more consistent evidence for a relationship
specifically between short sleep duration (<5-6 h) and type 2
diabetes development, although many studies have been
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insufficiently powered to thoroughly examine potential
confounding, especially confounding by baseline illness.
We report the largest prospective study to examine
longitudinal associations between baseline sleep duration and
future, incident CVD and type 2 diabetes. Specifically, we
sought to determine the extent to which observed associations
could be explained by confounding or effect modification by
pre-existing illness or functional impairment.
Materials and Methods
The study sample comprised participants in the 45 and Up
Study, a cohort study of 241,949 adults residing in the state of
New South Wales (NSW), Australia. Participants were
randomly selected from the Medicare Australia enrolment
database, with ~18% of those contacted joining the study. The
Medicare Australia database lists all Australian citizens.
Although not necessarily representative of the entire
population, the Study includes information about a large,
heterogeneous group of adults and provides robust meaningful
comparisons of outcomes based on internal comparisons
within the cohort [21]. Consenting participants completed a
comprehensive questionnaire and provided written, informed
consent for linkage of baseline data to health databases.
Questionnaires are available at http://www.45andup.org.au.
Ethics Statement
The 45 and Up Study received ethics approval from the
University of NSW Human Research Ethics Committee. Ethics
approval to use the data for this report was obtained from the
NSW Population and Health Services Ethics Committee.
Exposure and covariates
The self-report questionnaire included the question “About
how many hours in each 24 hour day do you usually spend
sleeping?” Continuous responses were recoded into six ordinal
categories, consistent with existing research: <6 h, 6 h (i.e. 6-
<7 h), 7 h (7-<8 h), 8 h (8-<9 h), 9 h (9-<10 h) and ≥10 h.
Serious illness was defined as self-reported, doctor-diagnosed
current cancer (past month treatment for any cancer excluding
non-melanoma skin cancer), or previously diagnosed cancer,
heart disease, stroke or diabetes (based on self-report and
current medications). These definitions were chosen to follow
the Charlson comorbidity index [22] as closely as possible.
Physical function was measured using the Medical Outcomes
Study Physical Functioning (MOS-PF) scale, using coding as
previously described [23]. Baseline health status was nominally
defined as “healthy” for individuals reporting no serious illness
at baseline and MOS-PF ≥75, and “less healthy” for individuals
reporting serious illness at baseline or MOS-PF <75. Additional
covariates were also coded for inclusion in statistical models.
These included gender, age in 5-year groups, education (<11
years, school certificate, higher school certificate, some tertiary
education, or University degree or higher), marital status
(single, widowed, divorced/separated, or married/de facto),
residential remoteness (major city, regional area, or remote
area), alcohol consumption (0, 1-7, 8-14, or >15 drinks per
week), smoking status (never, former, or current), health
insurance status (private insurance/veterans card or none),
annual household pre-tax income (<$AU 10,000, $10,000-
$30,000, $30,000-$70,000, or “I would rather not answer the
question”), body mass index (<18·5, 18·5-25, 25-30, or >30)
and sufficient physical activity (≥30 min per day or <30 min per
day).
Outcomes
Baseline data were linked to hospital admission data from
the NSW Admitted Patient Data Collection (APDC: to June
2010) and mortality data from the NSW Registry of Births,
Deaths and Marriages (RBDM: to June 2010). The NSW APDC
chronicles all hospitalisations in NSW, including dates of
admission and discharge, the primary diagnostic reason for
admission, and any additional diagnoses present. Diagnoses
were described using the International Statistical Classification
of Diseases and Related Health Problems, 10th Revision,
Australian Modification (ICD10-AM) [24]. Incident
cardiovascular disease (CVD) was defined as hospitalisation
due to ischaemic heart disease (primary diagnosis of ICD10
code prefix I20 – I25), ischaemic stroke (primary ICD10 code
prefix I63) or peripheral vascular disease (primary ICD10 code
prefix I74), excluding day-only admissions. Type 2 diabetes
was defined as overnight hospital admission for any reason,
where a type 2 diabetes diagnosis was recorded in one of the
first twenty ICD10 field codes. We note that this approach will
underestimate the incidence of type 2 diabetes, since those
developing type 2 diabetes but not admitted to hospital during
follow-up will not be identified.
Statistical analyses
Multivariate associations between sleep duration and each
clinical outcome were assessed using Cox proportional
hazards models, with time-to-event specified as the outcome.
For type 2 diabetes, time from enrolment to the first
hospitalisation recording a type 2 diabetes diagnosis was
treated as the approximate time to type 2 diabetes onset. For
each outcome, three multivariate models were fitted. For all
models, individuals missing data for sleep duration, age, sex,
physical functioning or prior serious illness were excluded.
Individuals reporting the specified outcome at baseline (CVD or
type 2 diabetes) were also excluded from analyses of the
respective outcome, to focus estimation on incident disease.
We defined prevalent CVD as self-reported heart disease,
stroke, or treatment for heart disease, and prevalent type 2
diabetes as self-reported diabetes or anti-diabetic medication
use. Model 1 included all eligible participants and was adjusted
only for age and sex. Model 2 included the same participants
as Model 1, but was adjusted for all defined covariates (see
Methods) explaining a significant proportion of outcome
variation in a partial likelihood ratio test (nominal P<0·1).
Multiplicative interaction terms between sleep duration and: a)
sex and; b) baseline health status were also assessed, to
investigate potential effect modification. If either interaction test
reached P<0·1 in a partial likelihood ratio test, effects were
reported separately for both categories of the covariate. Model
3 included the same comprehensive set of covariates and
interaction terms as Model 2 but additionally excluded all
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participants reporting serious illness at baseline (current/past
cancer, diagnosed/treated heart disease, stroke, or diabetes),
to reduce the potential for confounding or reverse causation by
co-morbid baseline illness. Multivariate models were built using
a backward, step-wise approach previously described [25] and
fitted using Stata v11.1 software. Each model satisfied the
proportional hazards assumption. A flow diagram detailing the
exclusions, sample size and covariates used in each analysis
model is provided in Figure S1.
Meta-analysis of prospective studies assessing the
relationship between short sleep and incident diabetes
Previous prospective studies assessing the relationship of
short sleep with incident diabetes were identified from the
literature, by searching the MEDLINE and EMBASE databases
using the terms “sleep duration” and “diabetes” and
(“prospective” or “cohort” or “longitudinal”), as previously
described [20]. To be included in the meta-analysis,
prospective studies were required to address incident diabetes
in multivariate analyses of at least 500 individuals. If multiple,
multivariate models were fitted, we recorded the effect estimate
least likely to have been confounded by baseline illness or
reverse causation, based on covariate adjustment or sensitivity
analyses. Effect estimates reported as odds ratios, hazard
ratios or risk ratios were treated as equivalent, since effect
estimates and outcome prevalences were low [26]. Pooling
was performed via fixed-effect Mantel-Haenszel meta-analysis
using Stata v11.1. Between-study heterogeneity was
investigated using Cochran’s Q statistic and the I2 metric.
Publication bias was assessed from the funnel plot, using
Egger’s regression test for asymmetry [27].
Results
The baseline dataset included 241,949 adults aged 45 years
and older, of which 29,561 were excluded due to missing data
for sleep duration, age, sex, physical functioning or serious
illness. Table 1 summarises sociodemographic and health
characteristics by sleep duration for the remaining 212,388
participants. The majority reported 7 h (24%) or 8 h (40.7%)
daily sleep. Sleep duration showed significant association with
all sociodemographic and health-related covariates in
univariate analyses (P<0·001; see Table 1).
Analyses of CVD using Model 1 and 2 included 181,544
individuals without prevalent CVD, of whom 5,814 were
hospitalised for CVD during follow-up (mean duration: 2·3 y).
Model 1, which was adjusted only for age and sex, suggested
association of short sleep (<6 h: HR=1·16 [95% CI: 1·01-1·34],
P=0·041), with incident CVD. Model 2, which incorporated
adjustment for a comprehensive set of covariates, showed
significant interaction between sleep duration and baseline
health status upon CVD risk (Pinteraction=0·01), indicating
heterogeneity of the sleep duration effect between the two
health groups. Sub-group analyses revealed a significant
association of short sleep (<6 h) with CVD in less healthy
individuals (HR=1·38 [95% CI: 1·12-1·70], P=0·002), but not in
healthy individuals (HR=0·92 [0·75-1·14]). Long sleep (≥10 h)
showed no significant association with CVD risk in either health
group.
Model 3 excluded a further 24,642 individuals reporting
either baseline type 2 diabetes or current/past cancer. Among
the remaining 156,902 individuals, there were 4,852 incident
cases of CVD (4,214 cases of ischaemic heart disease, 587
cases of ischaemic stroke and 51 cases of peripheral vascular
disease). In this model, which excluded individuals with a range
of serious illnesses at baseline, no sleep duration category was
significantly associated with incident CVD (all P>0·2; see Table
2 and Figure 1) and there was also no evidence of interaction
between sleep duration and health status upon CVD risk
(Pinteraction=0·1).
Analyses of type 2 diabetes using Model 1 and 2 included
192,728 individuals without type 2 diabetes, among whom
there were 4,648 recorded incident cases of type 2 diabetes.
Model 1, which was adjusted only for age and sex, showed
association of short sleep (<6 h: HR=1·28 [95% CI: 1·10-1·49],
P=0·002) with the development of type 2 diabetes. Model 2,
which was adjusted for a range of additional covariates,
showed similarly positive association of short sleep with type 2
diabetes (HR=1·23 [95% CI: 1·06-1·44], P=0·007), with no
Table 1. Sociodemographic and health-related factors by self-reported sleep duration in the 45 and Up Study (N=212,388).
 <6 h 6 h 7 h 8 h 9 h ≥10 h P
 N=7,311 N=25,487 N=50,979 N=86,502 N=25,616 N=16,493  
Age (mean ± SD) 64.4 ± 11.9 61.6 ± 10.9 60.1 ± 10.1 61.7 ± 10.6 64.6 ± 11.2 68.6 ± 12.1 <0.001
Male gender (%) 41.8 46.3 48.1 46.2 47.7 53.8 <0.001
Tertiary education (%) 41.4 54.1 62.3 57.9 54.4 44.8 <0.001
Married (%) 61.3 70.3 77.1 78.0 77.9 69.0 <0.001
Urban residence (%) 47.6 49.7 49.7 43.5 39.0 39.7 <0.001
Private health insurance (%) 51.4 64.3 72.5 68.6 65.1 53.6 <0.001
Sufficient physical activity (%) 59.6 67.2 72.3 70.7 70.0 53.7 <0.001
Current smoker (%) 11.0 9.2 6.8 6.3 5.6 8.4 <0.001
Current drinker (>1 per day) (%) 23.6 27.9 32.5 33.3 35.3 31.1 <0.001
Obese (%) 25.3 23.1 19.3 19.8 19.7 25.1 <0.001
Existing illness/functional limitation (%) 55.5 38.9 29.6 34.2 43.0 65.3 <0.001
doi: 10.1371/journal.pone.0082305.t001
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interaction of sleep duration with baseline health status
(Pinteraction=0·8). Model 3 excluded a further 35,826 individuals
reporting CVD or current/past cancer. Among the remaining
156,902 individuals, there were 3,641 recorded incident cases
of type 2 diabetes. In this model, similar association of short
sleep with elevated type 2 diabetes was observed (HR=1·29
[95% CI: 1·08-1·53], P=0·004), with no confounding or effect
modification by baseline health status (Pinteraction=0·2) (Table 3).
Table 2. Association of sleep duration with incident cardiovascular disease (CVD) in the 45 and Up Study.
 Model 1a Model 2b Model 3c
Sleep duration HRd Healthy HR Less Healthy HR HR Events/pye
<6 h 1·16 (1·01-1·34)* 0·92 (0·75-1·14) 1·38 (1·12-1·70)** 1·03 (0·88-1·21) 165/11,332
6 h 1·09 (1·00-1·19) 1·06 (0·96-1·18) 1·10 (0·93-1·31) 1·06 (0·96-1·17) 629/44,275
7 h 1 1 1 1 1,228/93,789
8 h 1·01 (0·94-1·07) 0·94 (0·87-1·02) 1·18 (1·03-1·35)* 0·98 (0·91-1·05) 1,956/150,222
9 h 1·01 (0·92-1·11) 0·95 (0·85-1·06) 1·14 (0·97-1·34) 0·98 (0·89-1·09) 555/40,405
≥10 h 1·10 (0·98-1·22) 0·97 (0·83-1·14) 1·17 (1·00-1·39) 1·00 (0·88-1·14) 319/20,647
Notes: Individuals with missing data for sleep duration, age, sex, physical functioning or baseline illness were excluded from all analyses. * P<0·05. ** P<0·01.
a Model 1 (N=181,544) included all eligible participants except those reporting CVD at baseline, and was adjusted for age and sex. b Model 2 (N=181,544) included all
eligible participants except those reporting CVD at baseline, and was adjusted for age, sex, education, marital status, residential remoteness, alcohol consumption, smoking
status, health insurance status, income, body mass index, physical activity and baseline health status. Results are presented separately for healthy and less healthy
participants, as significant interaction between sleep duration and health status was observed. c Model 3 (N=156,902) excluded all participants reporting any serious illness
at baseline (current/past cancer, or diagnosed/ treated heart disease, stroke or type 2 diabetes), and was adjusted for the same set of covariates as Model 2. d Hazard ratio
with 95% confidence interval, representing the estimated risk of CVD for the specified category of sleep duration, compared with the reference category of 7 h. e Number of
cardiovascular disease (coronary heart disease, ischaemic stroke or peripheral vascular disease) hospitalisations/total person years at risk during follow-up.
doi: 10.1371/journal.pone.0082305.t002
Figure 1.  Hazard ratio for incident cardiovascular disease (CVD) and type 2 diabetes by sleep duration category in the 45
and Up Study.  The plots shows hazard ratios with 95% confidence intervals for the specified category of sleep duration, compared
with 7 h, after adjusting for potential confounders. Analyses excluded individuals reporting any serious illness at baseline (cancer,
heart disease, stroke or diabetes).
doi: 10.1371/journal.pone.0082305.g001
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Meta-analysis of prospective studies assessing the
relationship between short sleep and incident diabetes
Results from ten studies qualified for inclusion in the meta-
analysis of association between short sleep and diabetes (see
Table 4). These included 447,124 participants of predominantly
European ancestry, excepting two studies (combined
N=10,079) conducted in Japanese populations [28]. One study
reported results separately for men and women [18], and
another for participants with and without a family history of
diabetes [29]; for these, subgroup-specific estimates were
included as separate studies. All studies defined the outcome
as either incident type 2 diabetes or incident total diabetes, of
which ~90-95% is expected to represent type 2 diabetes [30].
Effect estimates from individual studies and the meta-analysis
are shown in Figure 2. There was low between-study
heterogeneity (I2=32·8%: p=0·13), and the overall association
of short sleep with diabetes risk was highly significant
(OR=1·33 [95%CI: 1·20, 1·48); p=4x10-8), with no evidence of
publication bias (Egger’s test p=0·15).
Discussion
To our knowledge, this represents the largest longitudinal
study assessing relationships between sleep duration and
future cardiometabolic disorders. After accounting for baseline
illness or functional impairment, there was no significant
association between baseline sleep duration and future
cardiovascular disease. In contrast, short sleep duration (<6 h)
was prospectively related to future, incident type 2 diabetes;
this result was corroborated via meta-analysis of 10
prospective studies including more than 440,000 total
participants.
Relationship of sleep duration with future
cardiovascular disease
This study offers insights into previously reported
relationships between sleep duration and cardiovascular
disease. The presence of CVD is known to affect an
individual’s sleeping pattern [31], and CVD often co-exists with
other health conditions influencing sleep duration and quality,
such as obesity, hypertension and type 2 diabetes [32].
However, few previous prospective studies reporting
associations between sleep duration and cardiovascular
outcomes have incorporated comprehensive measures of
baseline health or functional capacity. Some used binary
variables reflecting the presence or absence of a particular
health condition (e.g. hypertension, dyslipidaemia, cardiac
disease, diabetes). But among those with a specific illness,
there will be substantial variation in the severity of disease,
level of sleep disturbance and underlying cardiovascular
disease risk. For this reason, adjustment simply for the
presence or absence of disease is unlikely to deal adequately
with confounding.
Obviously, the assessment of the nature of any exposure-
outcome relationship is not dependent solely on any one piece
of evidence, but on a broader consideration of clinical,
biological, epidemiological and other data. The general lack of
consistency of findings regarding sleep duration and
cardiovascular disease, the known relationships of sleep
disturbance to baseline health [33], and lack of association of
sleep duration with CVD risk in healthy individuals in our study,
suggests that observed relationships between short and long
sleep and CVD risk may largely reflect the effects of pre-
existing disease.
Relationship of sleep duration with future type 2
diabetes
In contrast, our detection of a significant association between
short sleep duration (<6 h) and the development of type 2
diabetes was robust to all exclusions and covariate
adjustments. This association was not only statistically
significant, but also appears to be clinically important, with
short sleep associated with an estimated 30% increased risk of
T2D. Thus, our result reflects more than the statistical
Table 3. Association of sleep duration with incident type 2 diabetes in the 45 and Up Study.
 Model 1a Model 2b Model 3c
Sleep duration HRd HR HR Events/pye
<6 h 1·28 (1·10-1·49)** 1·23 (1·06-1·44)** 1·29 (1·08-1·53)** 147/11,335
6 h 1·03 (0·93-1·13) 1·01 (0·91-1·12) 1·00 (0·90-1·12) 438/44,521
7 h 1 1 1 921/94,111
8 h 1·01 (0·93-1·08) 1·00 (0·93-1·08) 1·00 (0·92-1·09) 1,500/150,728
9 h 1·00 (0·91-1·11) 1·00 (0·90-1·11) 0·99 (0·88-1·12) 410/40,565
≥10 h 1·09 (0·97-1·23) 1·05 (0·93-1·19) 1·03 (0·88-1·19) 225/20,737
Notes: ** P<0·01.
a Model 1 (N=192,728) included all eligible participants except those reporting type 2 diabetes at baseline, and was adjusted for age and sex. b Model 2 (N=192,728)
included all eligible participants except those reporting type 2 diabetes at baseline, and was adjusted for age, sex, education, marital status, residential remoteness, alcohol
consumption, smoking status, health insurance status, income, body mass index, physical activity and baseline health status. c Model 3 (N=156,902) excluded all
participants reporting any serious illness at baseline (current/past cancer, or diagnosed/ treated heart disease, stroke or type 2 diabetes), and was adjusted for the same set
of covariates as Model 2. d Hazard ratio with 95% confidence interval, representing the estimated risk of type 2 diabetes for the specified category of sleep duration,
compared with the reference category of 7 h. e Number of incident type 2 diabetes cases recorded/total person years at risk during follow-up.
doi: 10.1371/journal.pone.0082305.t003
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association of a clinically trivial effect due to large sample size.
The positive association is also compelling given that the same
exclusions and covariate adjustments abolished the
association between short sleep and CVD. Comprehensive
modelling provided no evidence for modification or confounding
of the type 2 diabetes association by baseline health status.
Furthermore, we found no evidence for an association of long
sleep with type 2 diabetes, which is widely suggested to reflect
residual confounding. These points all suggest a lack of
residual confounding, supporting a causal relationship between
short sleep and type 2 diabetes risk. While we cannot
completely exclude the possibility of residual confounding in
the studies retrieved for our meta-analysis, the high
consistency between the results of our study and those of
previous studies suggests an absence of systematic
confounding in the retrieved studies. The low heterogeneity
and lack of publication bias supports the validity of the meta-
analysis result.
Well-controlled laboratory studies also provide credible
evidence that sleep loss impairs glucose clearance and insulin
sensitivity, increasing type 2 diabetes risk. Sleep deprivation
has been shown to reduce glucose tolerance and insulin
sensitivity [34]. Lack of sleep also elevates concentrations of
the appetite-stimulating hormone ghrelin and decreases levels
of the satiety hormone leptin [35,36], leading to increased
hunger and appetite [37]. Sleep restriction is also associated
with disrupted cortisol and growth hormone secretion,
predisposing to insulin resistance and hepatic glucose output
[38], both of which increase type 2 diabetes risk.
Strengths of this study include the prospective design,
comprehensive data linkage, a large study population
containing thousands of objectively measured events, and an
internal control (analyses of incident CVD) to demonstrate the
effects of residual confounding. The use of such an internal
control is unique among observational studies to date.
Limitations of the study include modest response rate and a
relatively short period of follow-up, which may have decreased
the magnitude of observed associations with either CVD or
type 2 diabetes. There is also some degree of measurement
error including:
• Exposure misclassification since we were also not able to
distinguish between short sleep as a result of restricted
bedtime, or sleep disruption due to a sleep disorder; sleep
duration was also self-reported.
• For type 2 diabetes, measurement of time to onset was
imprecise because diabetes may have developed prior to the
hospital admission at which it was ascertained.
• Inability to ascertain individuals who developed type 2
diabetes, but were not admitted to hospital during follow-up.







Exposure (short sleep /
referent)  Outcome Covariate adjustments*
Ayas et al [14] USA 70,026 Women 10 y ≤ 5 h vs 8 h Total diabetes 1, 2, 9, 14, 18, 19, 21, 28, 34, 36, 37
Beihl et al [17] USA 654 Both 5 y ≤ 7 h vs 8 h Type 2diabetes 1, 4, 8, 10, 14, 21, 33, 36
Gangwisch et al [16] USA 8,992 Both 8-10 y ≤ 5 h vs 7 h Total diabetes 1, 2, 9, 10, 13, 26, 28
Hayashino et al [28] Japan 6,509 Both Median 4·2 y < 6 h vs 6-7 h Total diabetes 1, 18, 21, 28, 29, 33, 36, 38
Holliday et al (this
study) Australia 180,891 Both Mean 2·3 y < 6 h vs 7-8 h
Type 2
diabetes 1, 2, 5, 10, 16, 22, 26, 28, 31, 33, 36
Kita et al [29] Japan 3,570 Both 3-5 y ≤ 5 h vs > 7 h Total diabetes
1, 2, 6, 10, 15, 23, 28, 30, 33, 34, 36, 41. Notes:
effects reported separately for those with and
without a family history of diabetes.
Mallon et al [18] Sweden 1,170 Both 12 y ≤ 5 h vs > 5 h Total diabetes 1, 2, 9, 21, 25, 27, 36, 37. Notes: effects reportedseparately for men and women.
Von Ruesten et al
[39] Germany 23,620 Both 9-13 y < 6 h vs 7-8 h
Type 2
diabetes 2, 3, 6, 7, 10, 11, 17, 20, 21, 24, 28, 33, 35, 36, 40
Xu et al [15] USA 174,542 Both 7-10 y < 5 h vs 7-8 h Total diabetes
1, 2, 5, 7, 10, 12, 13, 14, 26, 33, 36. Notes:
Diabetes cases diagnosed within the first 3-4 y of
follow-up were excluded. Estimate is from an
analysis of non-smoking, nonobese, physically
active, healthy individuals.
Yaggi et al [40] USA 1,139 Men 15-17 y ≤ 5 h vs 7 h Total diabetes 1, 10, 21, 32, 36, 39
*. Covariate definitions: 1: age, 2: alcohol use, 3: antidepressant intake, 4: baseline glucose tolerance, 5: baseline health status, 6: BMI, 7: caffeine use, 8: clinic, 9:
depression, 10: education, 11: employment status, 12: energy intake, 13: ethnicity, 14: family history of diabetes, 15: fasting plasma glucose, 16: health insurance, 17: health
satisfaction, 18: high cholesterol, 19: hormone replacement, 20: hyperlipidaemia, 21: hypertension, 22: income, 23: job stress, 24: life satisfaction, 25: living arrangement,
26: marital status, 27: obesity, 28: physical activity, 29: potential diabetes history, 30: rate of sedentary work, 31: residential remoteness, 32: self-rated health, 33: sex, 34:
shift work, 35: sleeping disorders, 36: smoking, 37: snoring, 38: study intervention, 39: waist circumference, 40: waist-to-hip ratio, 41: working hours per week.
doi: 10.1371/journal.pone.0082305.t004
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The first of these (explosure misclassification) is likely to be
non-differential with regard to the outcome, and thus will
reduce power to detect an association between the exposure
and outcome. The second two errors are anticipated to each
bias estimated effects towards the null. Those who developed
diabetes prior to the hospitalisation at which diabetes was
ascertained will have an erroneously longer time to onset
coded in the Cox proportional hazards model, thus reducing
the apparent hazard (per unit time) associated with the
exposure. Further, inability to ascertain diabetes in cases not
hospitalised during follow-up means these unascertained
diabetic cases were included in the reference group for the
entire follow-up period. This will also reduce the apparent
hazard associated with the exposure. Taken together, each of
these errors is predicted to reduce our ability to detect an
association between sleep duration and diabetes. This makes
the observed association seem all the more robust. Our use of
a parallel design and identical cohort for assessing the
prospective association of sleep duration with both CVD and
type 2 diabetes is unique and provides strong internal support
for a causal relationship between short sleep and type 2
diabetes. These results have relevance for public health
programs seeking to reduce chronic disease risk.
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